Nyhet

CCBIO collaboration project achieved EU funding

The TRANSCAN program (European Research Area Network on Translational Cancer Research) has just announced their allocation of funding.

EU funding for Norwegian cancer research

Photo:

colourbox and CCBIO collage

Main content

By Eli Synnøve VidhammerPublished: 31.10.2014

One of ten chosen projects

A project that CCBIO’s Professor Lars A. Akslen participates in, were among the ten projects that were singled out. Norway contributes as a partner in three of these. The Bergen project focuses on genetics of malignant melanoma and is titled "Identification of genetic markers involved in development of metastasis
and second cancers in melanoma."

International cooperation

Four other countries are involved: Germany, the Netherlands, Italy and Latvia. Coordinator from the Norwegian side is Professor Anders Molven from Gades Laboratory for Pathology, Department of Clinical Medicine, University of Bergen.

Drs. Per Helsing and Per A. Andresen at Oslo University Hospital are also partners in the Norwegian node. The project is directed by Prof. Rajiv Kumar in Heidelberg, a long-time collaborator of Akslen and Straume at CCBIO.

TRANSCAN is a European Research Area Network funded by the European Commission under the Seventh Framework Programme (FP7).

TRANSCAN is a collaborative network of ministries, funding agencies and research councils with programmes in translational cancer research. The network is composed of 25 partners from 19 European and Associated countries.

Objective
To contribute to the building of the European Research Area through the coordination of activities of national and regional translational cancer research funding organisations, aiming at the integration of basic, clinical and epidemiological cancer research and facilitation of transnational cancer funding in Europe with the ultimate aim to streamline EU-wide cancer screening, early diagnosis, prognosis, treatment and care.